

Sabina Antonela Antoniu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8965472/publications.pdf>

Version: 2024-02-01

125
papers

1,031
citations

567144

15
h-index

580701

25
g-index

126
all docs

126
docs citations

126
times ranked

1574
citing authors

#	ARTICLE	IF	CITATIONS
1	UPLIFT Study: the effects of long-term therapy with inhaled tiotropium in chronic obstructive pulmonary disease. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 719-722.	0.9	61
2	Targeting RhoA/ROCK pathway in pulmonary arterial hypertension. <i>Expert Opinion on Therapeutic Targets</i> , 2012, 16, 355-363.	1.5	50
3	Crizotinib for EML4-ALK positive lung adenocarcinoma: a hope for the advanced disease?. <i>Expert Opinion on Therapeutic Targets</i> , 2011, 15, 351-353.	1.5	46
4	Pirfenidone for the treatment of idiopathic pulmonary fibrosis. <i>Expert Opinion on Investigational Drugs</i> , 2006, 15, 823-828.	1.9	38
5	Targeting PDGF pathway in pulmonary arterial hypertension. <i>Expert Opinion on Therapeutic Targets</i> , 2012, 16, 1055-1063.	1.5	38
6	Inhaled colistin for lower respiratory tract infections. <i>Expert Opinion on Drug Delivery</i> , 2012, 9, 333-342.	2.4	37
7	Determinants of the Hesitancy toward COVID-19 Vaccination in Eastern European Countries and the Relationship with Health and Vaccine Literacy: A Literature Review. <i>Vaccines</i> , 2022, 10, 672.	2.1	35
8	Targeting the TNF- $\hat{\pm}$ pathway in sarcoidosis. <i>Expert Opinion on Therapeutic Targets</i> , 2010, 14, 21-29.	1.5	33
9	Measuring fatigue as a symptom in COPD. <i>Chronic Respiratory Disease</i> , 2015, 12, 179-188.	1.0	31
10	New therapeutic options in the management of COPD – focus on roflumilast. <i>International Journal of COPD</i> , 2011, 6, 147.	0.9	26
11	Predictors of Mortality in Patients with COPD and Chronic Respiratory Failure: The Quality-of-Life Evaluation and Survival Study (QuESS): A Three-Year Study. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2016, 13, 130-138.	0.7	26
12	Anti-TNF- $\hat{\pm}$ therapies in chronic obstructive pulmonary diseases. <i>Expert Opinion on Investigational Drugs</i> , 2008, 17, 1203-1211.	1.9	23
13	Impact of fatigue in patients with chronic obstructive pulmonary disease: results from an exploratory study. <i>Therapeutic Advances in Respiratory Disease</i> , 2016, 10, 26-33.	1.0	23
14	Cyclophosphamide for scleroderma interstitial lung disease. <i>Expert Opinion on Investigational Drugs</i> , 2007, 16, 393-395.	1.9	21
15	Adherence to inhaled therapy in COPD: effects on survival and exacerbations. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2010, 10, 115-117.	0.7	19
16	Novel inhaled combined antibiotic formulations in the treatment of <i>Pseudomonas aeruginosa</i> airways infections in cystic fibrosis. <i>Expert Review of Anti-Infective Therapy</i> , 2015, 13, 897-905.	2.0	17
17	Infliximab for the therapy of chronic sarcoidosis. <i>Expert Opinion on Investigational Drugs</i> , 2007, 16, 753-756.	1.9	16
18	Effects of inhaled therapy on biomarkers of systemic inflammation in stable chronic obstructive pulmonary disease. <i>Biomarkers</i> , 2010, 15, 97-103.	0.9	15

#	ARTICLE	IF	CITATIONS
19	Inhaled ciprofloxacin for chronic airways infections caused by <i>Pseudomonas aeruginosa</i> . Expert Review of Anti-Infective Therapy, 2012, 10, 1439-1446.	2.0	15
20	Nintedanib (BIBF 1120) for IPF: a tomorrow therapy?. Multidisciplinary Respiratory Medicine, 2012, 7, 41.	0.6	15
21	Therapeutic Approaches in Hereditary Angioedema. Clinical Reviews in Allergy and Immunology, 2011, 41, 114-122.	2.9	14
22	Mepolizumab for difficult-to-control asthma with persistent sputum eosinophilia. Expert Opinion on Investigational Drugs, 2009, 18, 869-871.	1.9	13
23	Pitrakinra for asthma. Expert Opinion on Biological Therapy, 2010, 10, 1609-1615.	1.4	13
24	Ciprofloxacin DPI in non-cystic fibrosis bronchiectasis: a Phase II randomized study. Expert Opinion on Investigational Drugs, 2013, 22, 671-673.	1.9	13
25	Targeting 5-lipoxygenase-activating protein in asthma and chronic obstructive pulmonary disease. Expert Opinion on Therapeutic Targets, 2014, 18, 1285-1292.	1.5	13
26	Pharmacological strategies for smoking cessation in patients with chronic obstructive pulmonary disease: a pragmatic review. Expert Opinion on Pharmacotherapy, 2021, 22, 835-847.	0.9	13
27	Cytokine Antagonists for the Treatment of Asthma. BioDrugs, 2009, 23, 241-251.	2.2	12
28	GM-CSF pathway correction in pulmonary alveolar proteinosis. Expert Opinion on Biological Therapy, 2010, 10, 1357-1365.	1.4	12
29	Pharmacotherapy of cough-variant asthma. Expert Opinion on Pharmacotherapy, 2007, 8, 3021-3028.	0.9	11
30	Targeting the angiotensin pathway in idiopathic pulmonary fibrosis. Expert Opinion on Therapeutic Targets, 2008, 12, 1587-1590.	1.5	11
31	Discontinued drugs 2011: pulmonary, allergy, gastrointestinal and arthritis. Expert Opinion on Investigational Drugs, 2012, 21, 1607-1618.	1.9	10
32	MP-376 (Aeroquin) for chronic <i>Pseudomonas aeruginosa</i> infections. Expert Opinion on Investigational Drugs, 2013, 22, 267-276.	1.9	10
33	Health status during hospitalisations for chronic obstructive pulmonary disease exacerbations: the validity of the Clinical COPD Questionnaire. Expert Review of Pharmacoeconomics and Outcomes Research, 2014, 14, 283-287.	0.7	10
34	Pulmonologists Adherence to the Chronic Obstructive Pulmonary Disease GOLD Guidelines: A Goal to Improve. Medicina (Lithuania), 2020, 56, 422.	0.8	10
35	Inhaled gentamicin in non-cystic fibrosis bronchiectasis: effects of long-term therapy. Expert Opinion on Pharmacotherapy, 2011, 12, 1191-1194.	0.9	9
36	Tralokinumab for uncontrolled asthma. Expert Opinion on Biological Therapy, 2013, 13, 323-326.	1.4	9

#	ARTICLE	IF	CITATIONS
37	Extra-respiratory symptoms in patients hospitalized for a COPD exacerbation: Prevalence, clinical burden and their impact on functional status. <i>Clinical Respiratory Journal</i> , 2019, 13, 735-740.	0.6	9
38	Sildenafil citrate for the treatment of pulmonary arterial hypertension. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 825-828.	0.9	8
39	Golimumab for severe asthma. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 1421-1423.	1.9	8
40	Raxibacumab for inhalational anthrax: an effective specific therapeutic approach?. <i>Expert Opinion on Investigational Drugs</i> , 2010, 19, 909-911.	1.9	8
41	Combined long-acting bronchodilator single therapy for COPD. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 139-142.	0.9	8
42	Infliximab for chronic obstructive pulmonary disease: towards a more specific inflammation targeting?. <i>Expert Opinion on Investigational Drugs</i> , 2006, 15, 181-184.	1.9	7
43	Update on models of pulmonary fibrosis therapy for preclinical drug research. <i>Expert Opinion on Drug Discovery</i> , 2009, 4, 939-946.	2.5	7
44	Lebrikizumab for the treatment of asthma. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 1239-1249.	1.9	7
45	Pirfenidone for the treatment of idiopathic pulmonary fibrosis: therapeutic potential prompts further investigation. <i>Expert Opinion on Investigational Drugs</i> , 2005, 14, 1443-1447.	1.9	6
46	Daclizumab a novel corticosteroid-sparing therapy for asthma?. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 369-371.	1.9	6
47	Predictors of depression in chronic obstructive pulmonary disease patients. <i>Expert Review of Respiratory Medicine</i> , 2011, 5, 333-335.	1.0	6
48	Varenicline for smoking cessation intervention in chronic obstructive pulmonary disease. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 2595-2597.	0.9	6
49	Hospitalizations for chronic obstructive pulmonary disease exacerbations and their impact on disease and subsequent morbidity and mortality. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2013, 13, 187-189.	0.7	6
50	Fresh from the designation pipeline: orphan drugs recently designated in the European Union (November 2012 – January 2013). <i>Expert Opinion on Orphan Drugs</i> , 2013, 1, 499-505.	0.5	6
51	Monoclonal antibodies for asthma and chronic obstructive pulmonary disease. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 257-268.	1.4	6
52	Investigational inhaled therapies for non-CF bronchiectasis. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 139-146.	1.9	6
53	Frailty, a Dimension of Impaired Functional Status in Advanced COPD: Utility and Clinical Applicability. <i>Medicina (Lithuania)</i> , 2021, 57, 474.	0.8	6
54	Etanercept for refractory asthma therapy. <i>Expert Opinion on Investigational Drugs</i> , 2006, 15, 1279-1281.	1.9	5

#	ARTICLE	IF	CITATIONS
55	Targeting the endothelin pathway in the idiopathic pulmonary fibrosis: the role of bosentan. Expert Opinion on Therapeutic Targets, 2008, 12, 1077-1084.	1.5	5
56	Effects of inhaled therapies on health-related quality of life in stable chronic obstructive pulmonary disease. Expert Review of Pharmacoeconomics and Outcomes Research, 2010, 10, 155-162.	0.7	5
57	Terguride for pulmonary arterial hypertension. Expert Opinion on Therapeutic Targets, 2011, 15, 1333-1335.	1.5	5
58	Cystic fibrosis transmembrane regulator potentiators as promising cystic fibrosis therapies. Expert Opinion on Investigational Drugs, 2011, 20, 423-425.	1.9	5
59	Evaluation of inhaled tiotropium in asthma, uncontrolled with standard combination therapy. Expert Opinion on Pharmacotherapy, 2013, 14, 967-969.	0.9	5
60	Nivolumab for advanced non-small cell lung cancer: an immunologically-mediated tumor checkout. Annals of Translational Medicine, 2016, 4, 201-201.	0.7	5
61	Sildenafil for pulmonary arterial hypertension: when blue turns into white. Expert Opinion on Pharmacotherapy, 2006, 7, 1801-1810.	0.9	4
62	Inhaled therapy for stable chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy, 2007, 8, 777-785.	0.9	4
63	PDE5 inhibitors for cystic fibrosis: can they also enhance chloride transport?. Expert Opinion on Investigational Drugs, 2008, 17, 965-968.	1.9	4
64	Triple inhaled therapy in stable chronic obstructive pulmonary disease: the earlier, the better?. Expert Opinion on Pharmacotherapy, 2010, 11, 1039-1042.	0.9	4
65	Tiotropium therapy and mortality risk in COPD patients: the most severe, the most protected?. Expert Opinion on Pharmacotherapy, 2010, 11, 1439-1441.	0.9	4
66	Bedoradrine for treating asthma and chronic obstructive pulmonary disease. Expert Opinion on Investigational Drugs, 2014, 23, 1149-1156.	1.9	4
67	Epratuzumab for systemic lupus erythematosus. Expert Opinion on Biological Therapy, 2014, 14, 1045-1047.	1.4	4
68	Nivolumab for advanced non-small cell lung cancer: an evaluation of a phase III study. Expert Review of Anticancer Therapy, 2016, 16, 165-167.	1.1	4
69	Romanian Guidelines for the Diagnosis and Treatment of GERD-induced Respiratory Manifestations. Journal of Gastrointestinal and Liver Diseases, 2022, 31, 119-142.	0.5	4
70	Treatment of fibrous dysplasia: focus on denosumab. Expert Opinion on Biological Therapy, 2022, 22, 397-405.	1.4	4
71	Histone deacetylase pathway: an evolving therapeutic target in chronic obstructive pulmonary disease. Expert Opinion on Therapeutic Targets, 2006, 10, 329-332.	1.5	3
72	Inhaled corticosteroids in COPD: systemic effects of a local therapy?. Expert Opinion on Pharmacotherapy, 2008, 9, 3271-3273.	0.9	3

#	ARTICLE	IF	CITATIONS
73	Somatostatin analogs for idiopathic pulmonary fibrosis therapy. Expert Opinion on Investigational Drugs, 2008, 17, 1137-1140.	1.9	3
74	Ciclesonide therapy in asthma: a potential effect on small airway inflammation?. Expert Opinion on Pharmacotherapy, 2009, 10, 917-919.	0.9	3
75	Tiotropium in the treatment of asthma. Expert Opinion on Pharmacotherapy, 2011, 12, 489-491.	0.9	3
76	Palliative care outcome measures in COPD patients: a conceptual review. Expert Review of Pharmacoeconomics and Outcomes Research, 2016, 16, 267-274.	0.7	3
77	Benralizumab as a potential treatment of asthma. Expert Opinion on Biological Therapy, 2017, 17, 895-900.	1.4	3
78	Belimumab and antipneumococcal vaccination in patients with systemic lupus erythematosus. Expert Review of Clinical Immunology, 2018, 14, 175-177.	1.3	3
79	Pharmacotherapy options in pulmonary alveolar proteinosis. Expert Opinion on Pharmacotherapy, 2020, 21, 1359-1366.	0.9	3
80	Novel amikacin inhaled formulation for the treatment of lower respiratory tract infections. Drugs of Today, 2013, 49, 683.	0.7	3
81	Inhaled interferons beta and SARS-COV2 infection: a preliminary therapeutic perspective. Expert Review of Respiratory Medicine, 2022, 16, 257-261.	1.0	3
82	Concern about rise in AIDS in Romanian adults. Lancet, The, 2000, 356, 1090.	6.3	2
83	Non-prostanoid prostacyclin agonists for the treatment of pulmonary arterial hypertension. Expert Opinion on Investigational Drugs, 2006, 15, 327-330.	1.9	2
84	Formoterol as a rescue medication for asthma. Expert Opinion on Pharmacotherapy, 2006, 7, 2439-2441.	0.9	2
85	Targeting platelet-derived growth factor with imatinib in idiopathic pulmonary arterial hypertension. Expert Opinion on Therapeutic Targets, 2009, 13, 381-383.	1.5	2
86	Targeting the toll-like receptor 7 pathway in asthma: a potential immunomodulatory approach?. Expert Opinion on Therapeutic Targets, 2011, 15, 667-669.	1.5	2
87	Acridinium bromide in experimental asthma. Expert Opinion on Investigational Drugs, 2011, 20, 871-873.	1.9	2
88	Immune therapies for malignant mesothelioma. Expert Review of Anticancer Therapy, 2014, 14, 965-973.	1.1	2
89	Efficacy of budesonide in collagenous colitis. Expert Opinion on Pharmacotherapy, 2014, 15, 2277-2279.	0.9	2
90	Fresh from the designation pipeline: orphan drugs recently designated in the European Union (September – November 2013). Expert Opinion on Orphan Drugs, 2014, 2, 311-315.	0.5	2

#	ARTICLE	IF	CITATIONS
91	Asthma and pregnancy: therapeutic challenges. Archives of Gynecology and Obstetrics, 2014, 290, 621-627.	0.8	2
92	Evaluating revefenacin as a therapeutic option for chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy, 2020, 21, 997-1004.	0.9	2
93	Challenges in Diagnosing Occupational Chronic Obstructive Pulmonary Disease. Medicina (Lithuania), 2021, 57, 911.	0.8	2
94	Marine-Derived Compounds for the Potential Treatment of Glucocorticoid Resistance in Severe Asthma. Marine Drugs, 2021, 19, 586.	2.2	2
95	High levels of smoking in Romanian doctors. Lancet, The, 2000, 356, 1420.	6.3	1
96	Daily versus intermittent corticosteroids for the treatment of mild persistent asthma. Expert Opinion on Pharmacotherapy, 2006, 7, 1235-1238.	0.9	1
97	Targeting tumour necrosis factor- α in corticosteroid-dependent asthma. Expert Opinion on Therapeutic Targets, 2006, 10, 471-473.	1.5	1
98	Discontinued drugs, 2007: pulmonary-allergy, dermatological, gastrointestinal and arthritis drugs. Expert Opinion on Investigational Drugs, 2008, 17, 1651-1661.	1.9	1
99	Discontinued drugs 2008: pulmonary and allergy. Expert Opinion on Investigational Drugs, 2009, 18, 1799-1805.	1.9	1
100	Effects of montelukast-desloratadine combination on early and late asthma responses. Expert Opinion on Pharmacotherapy, 2009, 10, 2577-2579.	0.9	1
101	Fudosteine effects on mucin production. Expert Opinion on Investigational Drugs, 2009, 18, 105-107.	1.9	1
102	Inhaled phosphodiesterase type 5 inhibitors for cystic fibrosis: a new therapy for systemic disease?. Expert Opinion on Investigational Drugs, 2011, 20, 713-715.	1.9	1
103	Roflumilast as add-on therapy to conventional inhalers in COPD: a cost-effectiveness analysis. Journal of Comparative Effectiveness Research, 2012, 1, 315-317.	0.6	1
104	Fresh from the designation pipeline: orphan drugs recently designated in the European Union. Expert Opinion on Orphan Drugs, 2013, 1, 249-253.	0.5	1
105	Fresh from the designation pipeline: orphan drugs recently designated in the European Union (June 2014). Expert Opinion on Orphan Drugs, 2014, 13, 107-111.	0.5	1
106	Outcome measures for palliative oxygen therapy: relevance and practical utility. Expert Review of Pharmacoeconomics and Outcomes Research, 2014, 14, 417-423.	0.7	1
107	Fresh from the designation pipeline: orphan drugs designated in the European Union (November 2014). Expert Opinion on Orphan Drugs, 2014, 13, 112-116.	0.5	1
108	Anthrax outbreak in Romania - under control. Lancet, The, 2000, 356, 664.	6.3	0

#	ARTICLE	IF	CITATIONS
109	Global initiative on COPD underway. Lancet, The, 2000, 356, 921.	6.3	0
110	Bosentan for the treatment of idiopathic pulmonary fibrosis. Expert Opinion on Investigational Drugs, 2008, 17, 611-614.	1.9	0
111	Itraconazole for severe asthma with fungal sensitivity. Expert Opinion on Pharmacotherapy, 2009, 10, 1231-1233.	0.9	0
112	Health status and chronic obstructive pulmonary disease severity. Expert Review of Pharmacoeconomics and Outcomes Research, 2011, 11, 399-401.	0.7	0
113	Discontinued drugs 2010: rheumatology, allergy and dermatology, pulmonary. Expert Opinion on Investigational Drugs, 2011, 20, 1175-1187.	1.9	0
114	Outpatient palliative care effectiveness: both patients and caregivers can gain. Expert Review of Pharmacoeconomics and Outcomes Research, 2013, 13, 575-577.	0.7	0
115	Fresh from the designation pipeline: orphan drugs recently designated in the European Union (March) Tj ETQq1 1 0,784314 rgBT /Overl 0,5	0.5	0
116	Discontinued drugs for pulmonary, allergy, gastrointestinal, arthritis (2012). Expert Opinion on Investigational Drugs, 2013, 22, 1453-1464.	1.9	0
117	Fresh from the designation pipeline: orphan drugs recently designated in the EU (March-April 2014). Expert Opinion on Orphan Drugs, 2014, 2, 957-960.	0.5	0
118	Fresh from the designation pipeline: orphan drugs recently designated in the European Union (December 2013-February 2014). Expert Opinion on Orphan Drugs, 2014, 2, 635-641.	0.5	0
119	Fresh from the designation pipeline: orphan drugs recently designated in the EU (June-July 2014). Expert Opinion on Orphan Drugs, 2014, 2, 1309-1313.	0.5	0
120	Efficacy of indacaterol as a single therapy versus salmeterol/fluticasone therapy in patients with milder chronic obstructive pulmonary disease. Expert Opinion on Pharmacotherapy, 2015, 16, 1539-1541.	0.9	0
121	Fresh from the designation pipeline: orphan drugs recently designated in the European Union (August-October 2014). Expert Opinion on Orphan Drugs, 2015, 3, 321-328.	0.5	0
122	Long-Term Bronchodilator Inhaled Therapy in COPD: The Role of Tiotropium Bromidum. Reviews on Recent Clinical Trials, 2009, 4, 89-98.	0.4	0
123	Humanistic Outcomes and Quality of Life. , 2012, , 211-220.		0
124	Fatigue is useful in characterising chronic obstructive pulmonary disease(COPD) frequent hospitalisations sub-phenotype. , 2016, , .		0
125	Palliative immunotherapy in the frail elderly: non-small cell lung cancer. BMJ Supportive and Palliative Care, 2021, , bmjpcare-2021-003223.	0.8	0